<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:admin="http://webns.net/mvcb/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
	<channel>
<title>Center for Sight Eye Info</title><link>http://www.center4sight.com/index.html</link><description>Eye Info</description><dc:language>en</dc:language><dc:creator>Mark Moran</dc:creator><dc:rights>Copyright 2007 Mark Moran</dc:rights><dc:date>2006-01-06T20:33:44-05:00</dc:date><admin:generatorAgent rdf:resource="http://www.realmacsoftware.com/" />
<admin:errorReportsTo rdf:resource="mailto:Mark Moran" /><sy:updatePeriod>hourly</sy:updatePeriod>
<sy:updateFrequency>1</sy:updateFrequency>
<sy:updateBase>2000-01-01T12:00+00:00</sy:updateBase>
<lastBuildDate>Sat, 23 Jun 2007 14:35:26 -0400</lastBuildDate><item><title>Avastin for macular degeneration</title><dc:creator>Mark Moran</dc:creator><dc:subject>Home</dc:subject><dc:date>2006-01-06T20:33:44-05:00</dc:date><link>http://www.center4sight.com/eyeinfo/eyetopics.html#unique-entry-id-5</link><guid isPermaLink="true">http://www.center4sight.com/eyeinfo/eyetopics.html#unique-entry-id-5</guid><content:encoded><![CDATA[AVASTIN is the parent molecule of LUCENTIS (both produced by GENENTECH), a drug similar to Macugen that inhibits VEGF (the chemical that causes wet macular degeneration-new leaking blood vessels to grow under the retina).   However, it is &ldquo;supercharged&rdquo; in the sense that it inhibits all forms of VEGF not just VEGF 165 like Macugen.   Studies have shown that a significant number of patients may actually have an improvement in vision following the injection of Lucentis.


However, Lucentis is not yet approved by the FDA and is not yet available (it may take a year or more).   Avastin is available for use for metstatic colon cancer.   It has been given intravenously for wet macular degeneration, but serious systemic side effects may occur. (hypertension, heart attacks and strokes).   A small study has shown that patients given intravitreal AVASTIN may improve vision and may be superior to Macugen.   This is an off-label use and not yet approved by FDA, and is not currently covered by Medicare, but is available to retinal specialists for office use.


The systemic side effects are eliminated when used in the eye.   The treatment may have to be repeated every 4-6 weeks and requires pre and post antibiotic drops to decrease the risk of an infection in the eye after the injection.   If you have questions regarding Macular Degeneration and what treatment you may right for you, call our office to schedule an appointment with Dr.   Ross, our retinal specialist.]]></content:encoded></item><item><title>Botox Injections</title><dc:creator>Mark Moran</dc:creator><category>Oculoplastic</category><dc:date>2005-12-31T12:00:51-05:00</dc:date><link>http://www.center4sight.com/eyeinfo/eyetopics.html#unique-entry-id-4</link><guid isPermaLink="true">http://www.center4sight.com/eyeinfo/eyetopics.html#unique-entry-id-4</guid><content:encoded><![CDATA[Purified botulinum toxin A (BotoxAE) has been in clinical use for over 20 years for various medical conditions including muscle spasms and nerve disorders.   First developed by ophthalmologists for eyelid spasm, Botox has now been shown to provide months of relief for persons suffering from frequent migraine and tension headaches.   It is also now FDA approved for cosmetic uses and is wonderful for lines around the eyes and forehead.


Dr.   Houman Ahdieh is certified to treat blepharospasms (spasms of the eyelids)and BOTOX treatments for patients that are interested in reducing or eliminating facial wrinkles.    He  can treat furrows in the forehead, crows feet around the eyes and frown lines that can be unattractive.


For more information on BOTOX check out our links.


BOTOX Cosmetic]]></content:encoded></item><item><title>SLT</title><dc:creator>Mark Moran</dc:creator><category>Glaucoma</category><dc:date>2005-11-02T15:59:51-05:00</dc:date><link>http://www.center4sight.com/eyeinfo/eyetopics.html#unique-entry-id-3</link><guid isPermaLink="true">http://www.center4sight.com/eyeinfo/eyetopics.html#unique-entry-id-3</guid><content:encoded><![CDATA[Rather than using medicines, SLT uses an advanced laser system to target only specific cells of the eye, cells that contain melanin, a natural pigment. ...  As a result, your body's own healing response helps lower the pressure in your eye.   SLT is an advancement over other lasers that have been used safely and effectively in the treatment of open-angle glaucoma for more than two decades.


...Unlike some glaucoma medications, there are no incidences of allergy or systemic side-effects with SLT.   Complications are minimal but may include temporary increase in eye pressure, inflammation, headache, iritis, blurred vision, eye pain, corneal edema, conjunctivitis, or corneal lesion.


...SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure.   Using a special wavelength and energy, the laser only affects pigmented (melanin containing) cells of your eye. 

...Safe: SLT is not associated with systemic side effects or the compliance and cost of medications.   Selective: SLT utilizes selective photothermolysis to target only specific cells, leaving the surrounding tissue in tact.   Smart: SLT stimulates the body's natural mechanisms to enhance outflow of the fluid in your eye. 

...Usually, SLT is performed in the physician's office and only takes a few minutes. ...  The laser application are made through a special microscope, similar to the one used for eye examinations.


...Your eye pressure may drop as quickly as a day or more after having SLT performed.   The doctor may treat the eye with anti-infammatory eye drops that you will continue to use after the procedure. ]]></content:encoded></item></channel>
</rss>